Beyond the Pink Ribbon: A Closer Look at Breast Cancer Progress
For Breast Cancer Awareness Month, Oranus Mohammadi, MD, discussed the remarkable progress made in improving survival rates for patients with breast cancer.
For Breast Cancer Awareness Month, Oranus Mohammadi, MD, discussed the remarkable progress made in improving survival rates for patients with breast cancer.
Lurbinectedin plus atezolizumab produced significant OS and PFS benefits as frontline maintenance for extensive-stage small cell lung cancer.
Ian Krop, MD, PhD, and Aditya Bardia, MD, MPH, FASCO, detail how TROP2-directed ADCs have generated excitement in breast cancer and other solid tumors.
Benjamin Adam Weinberg, MD, discusses the prognostic value of adjuvant ctDNA testing in CRC and the role of immune checkpoint inhibition in dMMR CRC.
The KEYNOTE-689 study evaluating pembrolizumab in this patient population met its primary end point of event-free survival.
NKT2152, a novel HIF2α inhibitor, produced responses in heavily pretreated advanced clear cell renal cell carcinoma.
The EMA has received a submission seeking the approval of darolutamide in combination with ADT in metastatic hormone-sensitive prostate cancer.
Hamilton et al. perform proteogenomic analyses to discover high-confidence candidate immunotherapeutic targets in neuroblastoma. Delta-like canonical notch ligand 1 (DLK1) is prioritized and validated. A DLK1-directed…
Cancer is a major and worsening global challenge. It is the leading cause of death and disease burden in most countries worldwide, with large inequalities…
Patients and caregivers will find support and camaraderie at Together Facing Lung Cancer, a free educational workshop. The program will feature a panel of Fox…
An abstract is unavailable.